Cyclerion Therapeutics, Inc. (KRSA) vs Stoke Therapeutics, Inc. (STOK)
Cyclerion Therapeutics, Inc. and Stoke Therapeutics, Inc. are both Biotechnology companies. Cyclerion Therapeutics, Inc. and Stoke Therapeutics, Inc. are of similar size ($1.7B and $1.6B). Cyclerion Therapeutics, Inc. grew revenue faster over the last twelve months: 30.8% against −86.2%. Cyclerion Therapeutics, Inc. has the higher net margin (0.00% vs −753.6%) and the higher return on invested capital (−115.4% vs −264.8%). Across the 15 metrics below, Cyclerion Therapeutics, Inc. leads on 9 and Stoke Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | KRSA | STOK | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (809.69%) | 0.00% |
| Net margin | 0.00% | (753.60%) | 0.00% |
| Free cash flow margin | 0.00% | (654.92%) | 0.00% |
| Return on equity | (98.22%) | (61.10%) | (57.72%) |
| Return on assets | (82.29%) | (53.41%) | (49.22%) |
| Return on invested capital | (115.40%) | (264.77%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack